Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.

Market Dynamics

Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.

However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.

Key features of the study:

• This report provides in-depth analysis of the global progressive supranuclear palsy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.

Detailed Segmentation:

• Global Progressive Supranuclear Palsy Treatment Market, By Drug Type:
  • Dopamine
  • Anticholinergic Agents
  • Tricyclic Antidepressants
  • Others
• Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Progressive Supranuclear Palsy Treatment Market, By Region:
  • North America
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
    • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • AbbVie Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Acorda Therapeutics Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Merck & Co. Inc.
  • UCB Biopharma
  • AlzProtect
  • Asceneuron Therapeutics
  • TauRx Pharmaceuticals
  • GlaxoSmithKline PLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.